cancer clinical trials for Myeloma/Plasma Cell Dyscrasia (ONC)

8 Myeloma/Plasma Cell Dyscrasia (ONC) clinical trials found. View a list of all cancer clinical trial types.

• A Phase 1 Multicenter, Open-Label Study to Determine the Recommended Dose and Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose For Each Add On Investigational Component

  Current Status: Open

  View links and contact information related to this clinical trial

• A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)

  Current Status: Open

  View links and contact information related to this clinical trial

• Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients

  Current Status: Open

  View links and contact information related to this clinical trial

• Expanded Access Protocol (EAP) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming For Commercial Release

  Current Status: Open

  View links and contact information related to this clinical trial

• Post Trial Access of Modakafusp Alfa (TAK-573) monotherapy or in Combination for the Treatment of Advanced Multiple Myeloma

  Current Status: Closed

  View links and contact information related to this clinical trial

• A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

  Current Status: Open

  View links and contact information related to this clinical trial

• Intermediate-Size Population Expanded Access Program (EAP) for cilta-cel Out-of-Specification (OOS) in Patients with Multiple Myeloma

  Current Status: Open

  View links and contact information related to this clinical trial

• A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

  Current Status: Open

  View links and contact information related to this clinical trial